Table 1. Baseline characteristics of study participants.
| DonorID | Age range
(years) |
Sex | IFN signature
(AU) 1 |
sSIGLEC-1 (ng/ml) 1, 2 | IL-2
(fg/ml) 3 |
sCD25
(pg/ml) 4 |
|---|---|---|---|---|---|---|
| SLE1
(IFN lo ) |
50–55 | F | -2.2 | 16.1 | 109.3 | 5,879.8 |
| SLE2
(IFN hi ) |
50–55 | F | 7.5 | 24.7 | 672.9 | 12,363.3 |
| HD | 50–55 | F | -5.2 | 4.8 | 108.9 | 3,193.7 |
Baseline demographic and molecular biomarkers characteristics for the study participants. Molecular biomarkers of disease activity, including the type I interferon transcriptional signature, the plasma concentration of soluble SIGLEC-1 and IL-2 were measured as described previously 8, 9 . 1Median IFN signature measured in this cohort of SLE patients was 0.06 AU (range = -11.43 - 14.36 AU). 2Median sSIGLEC-1 concentration measured in this cohort of SLE patients was 11.0 ng/ml (range = 2.4 - 53.3 ng/ml). 3Median IL-2 concentration measured with this assay was 93.9 fg/ml (range = <10 - 1,504.9 fg/ml) and 123.6 fg/ml (range = 19.3 - 2,527.0 fg/ml) in a cohort of healthy donors (N = 194) and SLE patients (N = 41), respectively. 4Median sCD25 concentration was 3,205.3 pg/ml (range = 1,622.0 - 12,875.6 pg/ml) and 3,254.6 pg/ml (range = 1,270.1 - 21,282.0 pg/ml) in a cohort of healthy donors (N = 141) and SLE patients (N = 41), respectively. AU, arbitrary units; HD, healthy donor; IFN, type I interferon; N/A, not available; sCD25, soluble CD25; SLE, systemic lupus erythematosus; sSIGLEC-1, soluble SIGLEC-1.